公开(公告)号：US20170152251A1

公开(公告)日：2017-06-01

申请号：US15325521

申请日：2014-07-18

Applicant: GREEN CROSS CORPORATION ,  LEGOCHEM BIOSCIENCES,INC.

Inventor： Soongyu CHOI ,  Jungsub CHOI ,  So-Hyun YOON ,  Yoo Hoon KIM ,  Jae Yeon KIM ,  Suk Ho LEE ,  Young Lag CHO ,  Ho Young SONG ,  Dae Yon LEE ,  Sung Yoon BAEK ,  Sang Eun CHAE ,  Tae Kyo PARK ,  Sung Ho WOO ,  Yong Zu KIM

IPC: C07D413/14

CPC classification number: C07D413/14 ,  A61K31/53 ,  A61P7/02 ,  A61P9/00 ,  A61P29/00 ,  C07B2200/13 ,  C07D253/065 ,  C07D409/10

Abstract: The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.

公开(公告)号：US20170368175A1

公开(公告)日：2017-12-28

申请号：US15544335

申请日：2016-01-15

Applicant: GREEN CROSS CORPORATION

Inventor： Yong Woon CHOI ,  Yoo Hoon KIM ,  Jungsub CHOI

IPC: A61K39/395 ,  A61K47/12 ,  A61K47/10 ,  A61K47/26 ,  A61K47/18

CPC classification number: A61K39/39591 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  C07K16/2863 ,  C07K2317/94

Abstract: The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.